Community 365 Roundtable: Ensuring equitable access to precision cancer medicine in Europe

Roundtable on Personalised Access Landscape 1 v2

09 October 2025 15:00 - 17:30 CEST

Online

Watch the recording below:

 

The European Cancer Organisation hosted on 9 October 2025 a high-level Community 365 Roundtable on personalised treatment: tailoring prevention, diagnosis, and strategies to the individual characteristics of each patient.

Rather than adopting a one-size-fits-all model, we need to optimise health outcomes by considering a person’s unique genetic makeup, environment and lifestyle. But how do we ensure this level of care reaches many more Europeans?

The roundtable brought together leading experts, policymakers, industry partners, and patient advocates to assess the current status of personalised oncology care and identify policy recommendations to expand access across all regions and patient groups.

Participants explored the full ecosystem required to make precision cancer medicine a standard part of care. The roundtable also informed current efforts to create ‘Essential Requirements for Quality Cancer Care: Precision Cancer Medicine’, helping shape a future where every patient has equitable access to innovative cancer solutions.

In this roundtable, we've:

  • Explored the key elements needed to build a strong and resilient precision cancer medicine ecosystem

  • Reviewed current European initiatives supporting access to precision cancer medicine and discuss where future action should be directed

  • Discovered practical and effective approaches to delivering precision cancer medicine at scale, ensuring patients across Europe can benefit

The roundtable was chaired by:

  • Rui Medeiros, Deputy Director at the Research Centre, Instituto Português de Oncologia (IPO Porto) & Board Member of the European Cancer Organisation.
  • Bettina Ryll, founder of the Melanoma Patient Network Europe (MPNE) & member of the first EU Cancer Mission Board & works on national and European PCM implementation at the Stockholm School of Economics Institute for Research.

Speakers

  • Rui Medeiros Deputy Director at the Research Centre, Instituto Português de Oncologia (IPO Porto) & Board Member of the European Cancer Organisation
  • Bettina Ryll Lead of Work Package 6 (WP6) 'Social Innovation for Access to PCM (Precision Cancer Medicine)' in the PRIME-ROSE project
  • Elizabeth Cartwright Consultant Medical Oncologist, The Royal Marsden Hospital
  • Vera Deneer Chair of the Dutch Pharmacogenetics Working Group
  • Pierluigi Fracasso Member of UEG Public Affairs Group
  • Ebba Hallersjö Hult Co-Founder & Head, Vision Zero Cancer
show all speakers (10)

Speakers

  • Rui Medeiros Deputy Director at the Research Centre, Instituto Português de Oncologia (IPO Porto) & Board Member of the European Cancer Organisation
  • Bettina Ryll Lead of Work Package 6 (WP6) 'Social Innovation for Access to PCM (Precision Cancer Medicine)' in the PRIME-ROSE project
  • Elizabeth Cartwright Consultant Medical Oncologist, The Royal Marsden Hospital
  • Vera Deneer Chair of the Dutch Pharmacogenetics Working Group
  • Pierluigi Fracasso Member of UEG Public Affairs Group
  • Ebba Hallersjö Hult Co-Founder & Head, Vision Zero Cancer
show all speakers (10)
  • Rui Medeiros Deputy Director at the Research Centre, Instituto Português de Oncologia (IPO Porto) & Board Member of the European Cancer Organisation
  • Bettina Ryll Lead of Work Package 6 (WP6) 'Social Innovation for Access to PCM (Precision Cancer Medicine)' in the PRIME-ROSE project
  • Elizabeth Cartwright Consultant Medical Oncologist, The Royal Marsden Hospital Read Bio
  • Vera Deneer Chair of the Dutch Pharmacogenetics Working Group Read Bio
  • Marco Di Donato Policy and Projects Manager, EUREGHA Read Bio
  • Pierluigi Fracasso Member of UEG Public Affairs Group Read Bio
  • Ebba Hallersjö Hult Co-Founder & Head, Vision Zero Cancer Read Bio
  • Dima Hamadeh Global Policy Strategy Director, Bristol Myers Squibb Read Bio
  • Peter Kapitein Patient Advocate, Inspire2Live Read Bio
  • Júlio Oliveira Coordinator of the Precision Oncology Program & Board member, IPO Porto Read Bio
  • Roberta Savli Executive Director Public Affairs, EFPIA
  • Leonie de Visser EMEA Disease Team Leader (Bladder), Johnson & Johnson Innovative Medicines Read Bio
  • Jan-Willem Van De Loo Senior Expert Cancer Research, European Commission Read Bio

Speakers

  • Rui Medeiros Deputy Director at the Research Centre, Instituto Português de Oncologia (IPO Porto) & Board Member of the European Cancer Organisation
  • Bettina Ryll Lead of Work Package 6 (WP6) 'Social Innovation for Access to PCM (Precision Cancer Medicine)' in the PRIME-ROSE project
  • Elizabeth Cartwright Consultant Medical Oncologist, The Royal Marsden Hospital
  • Vera Deneer Chair of the Dutch Pharmacogenetics Working Group
  • Pierluigi Fracasso Member of UEG Public Affairs Group
  • Ebba Hallersjö Hult Co-Founder & Head, Vision Zero Cancer
show all speakers (10)

Programme

15:00 - 15:10
Welcome and introductions
15:10 - 15:55
The precision cancer medicine eco-system
 

This session will provide a first focus on elements that any national and regional health system should aim to put in place to deliver sustainable precision cancer medicine access. It will explore what an effective ecosystem looks like in practice.

Co-chaired by Rui Medeiros, Deputy Director at the Research Centre, Instituto Português de Oncologia (IPO Porto) & Board Member of the European Cancer Organisation, and Leonie de Visser, EMEA Disease Team Leader (Bladder), Johnson & Johnson Innovative Medicines.

  • Bettina Ryll - Lead of Work Package 6 (WP6) 'Social Innovation for Access to PCM (Precision Cancer Medicine)' in the PRIME-ROSE project
  • Pierluigi Fracasso - Member of UEG Public Affairs Group
  • Ebba Hallersjö Hult - Co-Founder & Head, Vision Zero Cancer
  • Marco di Donato - Policy and Projects Manager, EUREGHA
15:55 - 16:40
Building on European investment in precision cancer medicine. Quo Vadis?
 

This session will reflect on the journey so far in the EU’s support towards the precision cancer medicine agenda, taking account of a selection of relevant EU supported projects. As the EU considers major changes to EU funding in the context of a new multiannual financial framework, we'll present an overview of the key recommendations from speakers and our audience for where and how EU investment makes, and can make, the greatest impact.

Co-chaired by Bettina Ryll, Lead of Work Package 6 (WP6) 'Social Innovation for Access to PCM (Precision Cancer Medicine)' in the PRIME-ROSE project, and Dima Hamadeh, Global Policy Strategy Director, Bristol Myers Squibb.

  • Peter Kapitein - Patient Advocate, Inspire2Live
  • Roberta Savli - Executive Director Public Affairs, EFPIA
  • Jan-Willem Van De Loo - Senior Expert Cancer Research, European Commission
16:40 - 17:25
Delivering quality and value for precision medicine at scale
 

This session aims at examining some case study approaches to unblocking barriers to precision cancer medicine access at national level, with the UK in inititial focus and thereafter drawing example and perspectives from those involved in approaches in other countries.

Chaired by Rui Medeiros, Deputy Director at the Research Centre, Instituto Português de Oncologia (IPO Porto) & Board Member of the European Cancer Organisation.

  • Sean Kelly - Member of the European Parliament (video address)
  • Júlio Oliveira - Coordinator of the Precision Oncology Program & Board member, IPO Porto
  • Vera Deneer - Chair of the Dutch Pharmacogenetics Group
  • Elizabeth Cartwright - Consultant Medical Oncologist, The Royal Marsden Hospital
17:25 - 17:30
Event conclusions and next steps

Speakers

  • Rui Medeiros Deputy Director at the Research Centre, Instituto Português de Oncologia (IPO Porto) & Board Member of the European Cancer Organisation
  • Bettina Ryll Lead of Work Package 6 (WP6) 'Social Innovation for Access to PCM (Precision Cancer Medicine)' in the PRIME-ROSE project
  • Elizabeth Cartwright Consultant Medical Oncologist, The Royal Marsden Hospital
  • Vera Deneer Chair of the Dutch Pharmacogenetics Working Group
  • Pierluigi Fracasso Member of UEG Public Affairs Group
  • Ebba Hallersjö Hult Co-Founder & Head, Vision Zero Cancer
show all speakers (10)

Speakers

  • Rui Medeiros Deputy Director at the Research Centre, Instituto Português de Oncologia (IPO Porto) & Board Member of the European Cancer Organisation
  • Bettina Ryll Lead of Work Package 6 (WP6) 'Social Innovation for Access to PCM (Precision Cancer Medicine)' in the PRIME-ROSE project
  • Elizabeth Cartwright Consultant Medical Oncologist, The Royal Marsden Hospital
  • Vera Deneer Chair of the Dutch Pharmacogenetics Working Group
  • Pierluigi Fracasso Member of UEG Public Affairs Group
  • Ebba Hallersjö Hult Co-Founder & Head, Vision Zero Cancer
show all speakers (10)